|
Each
tablet contains :
Composition:
Mycophenolate Mofetil
...................................................500
mg
Indications:
Mycophenolate is indicated for the prophylaxis of organ
rejection in patients receiving allogeneic renal,
cardiac or hepatic transplants. Mycophenolate should be
used concomitantly with cyclosporine and
corticosteroids.
Description:
The
salvage pathway of purine synthesis in lymphocytes is
less active than the de novo synthesis of purines.
Inosine monophosphate is converted to guanosine
monophosphate by inosine monophosphate dehydrogenase.
During T-cell activation, the activity of both types I
and II inosine monophosphate dehydrogenase enzymes
increases by tenfold. Mycophenolate mofetil is converted
in the liver by ester hydrolysis to mycophenolic acid,
which in turn non-competitively and reversibly inhibits
types I and II inosine monophosphate dehydrogenase
activity during DNA synthesis in the S phase of the cell
cycle. In the salvage pathway, guanine is converted to
guanine monophosphate by the enzyme hypoxanthine-guanine
phosphoribosyltransferase.
Dosage :
A dose of 1 g administered orally twice a day (daily
dose of 2 g) is recommended for use in renal transplant
patients or as per the physician’s advice.
Presentations:
10 tablets
MRP Retailer Stockist
880.00
704.00
633.60 | 
